nivolumab,etigilimab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['etigilimab', 'biomarker', 'marker ', 'mereo ', '$mreo']
mereo biopharma reports clinical update and interim biomarker analysis presented at esmo 2022 from activate phase 1b/2 open label study of etigilimab plus niv.. $mreo 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice